Critical Reviews™ in Therapeutic Drug Carrier Systems

ISSN for PRINT: 0743-4863

For Online Access

Best Paper Award Selection - Editorial Board Site

2003, Volume20

Issue 2&3

154 pages

DOI: 10.1615/CritRevTherDrugCarrierSyst.v20.i23

Issue price - $322.00

J. C. Murray
CRUK Tumour Cytokine Biology Group, Wolfson Digestive Diseases Centre, University Hospital, Nottingham NG7 24H, UK

S. Moein Moghimi
Molecular Targeting and Polymer Toxicology Group, School of Pharmacy and Biomolecular Sciences, Cockcroft Building, University of Brighton, Brighton BN2 4GJ, UK

The significance of the endothelial cell as a target for antitumor therapy has been recognized for some time, but so far the results of clinical trials exploiting this approach have not been encouraging. The subject is likely to gain new momentum, however, following a number of important recent findings that shed new light on the origins and nature of tumor vasculature. Coupled with rapid developments in the use of phage-displayed peptide libraries to characterize the human vascular map, as well as highly selective delivery systems, this new understanding of tumor vascular biology should provide many fresh and exciting avenues to explore.

DOI: 10.1615/CritRevTherDrugCarrierSyst.v20.i23.20 Download article, 14 pages

Article price - $35.00

<< Previous article   Next article >>